secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001193125-26-198588
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma licenses ex-China rights to anti-IgE mAb Ascendant-221; raises $30M; appoints new CEO
--------------------------------------------------------------------------------

- License with Ascendant Health Sciences: $15M upfront, up to $676.5M milestones, tiered high-single-to-low-double-digit royalties on ex-China sales.
- Concurrent private placement raises ~$28M net via pre-funded warrants and warrants at $11.00/unit to accredited investors including new CEO.
- New CEO Dr. Shao-Lee Lin appointed; participates in the private placement.
- Ascendant receives pre-funded warrants for 551,724 shares at $0.001; total potential dilution from warrants exceeds 4.6M shares.
- Company to seek stockholder approval for share issuances under Nasdaq rules; special meeting within 90 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526198588/0001193125-26-198588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526198588/d128047d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-198588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer